Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients

doi:10.5500/wjt.v4.i2.133

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6160)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

369

WORD

365

HTML

2836

Figures (1-1)

471

Tables (1-4)

187

Sum=4228

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

899

Download

1033

Sum=1932

Jun 24, 2014 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Research Report

World J Transplant. Jun 24, 2014; 4(2): 133-140
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.133

Full Size Figure Download Figure

Figure 1 Box plots of serum transforming growth factor-β (A) and serum Hyaluronic acid (B) in patients under calcineurin inhibitors or everolimus regime. TGF-β: Transforming growth factor-β; CNI: Calcineurin inhibitors.

Citation: Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant 2014; 4(2): 133-140
URL: https://www.wjgnet.com/2220-3230/full/v4/i2/133.htm
DOI: https://dx.doi.org/10.5500/wjt.v4.i2.133